stockrowENDRA Life Sciences Inc.
NDRA Healthcare Diagnostics & Research
- EPS
- +107.0%
- Free cash flow
- +15.0%
Quarter to June 2026, against a year earlier
Follow NDRA
Alert me
ENDRA Life Sciences Inc. (NDRA) EV/Sales
As of 5 November 2026, ENDRA Life Sciences Inc. (NDRA) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from −17.4× (September 2024) to 248× (April 2021); the current reading is higher than 19% of that period. That is below the Diagnostics & Research industry median of 5.2× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2018 | −3.4× | — |
| FY2017 | 13.5× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2018 | 17.0× | 25.96% |
| Dec 2017 | 13.5× | — |
| Sep 2017 | 0.0× | — |
| Jun 2017 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. compare | −1.5× |
| BIAF bioAffinity Technologies, Inc. compare | −0.2× |
| XWEL XWELL, Inc. compare | −0.1× |
| ADVB Advanced Biomed Inc. compare | n/m |
| MDXH MDxHealth SA compare | 0.8× |
| AWHL Aspira Women's Health Inc. compare | 1.2× |
| NDRA ENDRA Life Sciences Inc. | 1.9× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)